Trial Profile
A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon SIL) for Amatoxin Induced Hepatic Failure
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Silibinin (Primary)
- Indications Poisoning
- Focus Therapeutic Use
- Sponsors Madaus
- 01 Jul 2020 Status changed from recruiting to discontinued.
- 21 Dec 2017 Status changed from active, no longer recruiting to recruiting.
- 26 Oct 2017 Status changed from recruiting to active, no longer recruiting.